Who are Bictegravir (BIC)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dolutegravir (DTG), Switch to B/F/TAF, Cabotegravir Injectable Suspension, bictegravir/emtricitabine/tenofovir alafenamide, cabotegravir, CAB, Dolutegravir/Lamivudine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bictegravir-bic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bictegravir (BIC) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bictegravir (BIC) (Bictegravir (BIC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

marketed Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Bictegravir (BIC) (Bictegravir (BIC)) — National Institute of Allergy and Infectious Diseases (NIAID). Bictegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bictegravir (BIC) TARGET	Bictegravir (BIC)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Dolutegravir (DTG)	Dolutegravir (DTG)	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Cabotegravir Injectable Suspension	Cabotegravir Injectable Suspension	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
cabotegravir, CAB	cabotegravir, CAB	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

ViiV Healthcare · 12 drugs in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
Merck Sharp & Dohme LLC · 5 drugs in this class
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
Germans Trias i Pujol Hospital · 1 drug in this class
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
University of Colorado, Denver · 1 drug in this class
MU-JHU CARE · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bictegravir (BIC) — Competitive Intelligence Brief. https://druglandscape.com/ci/bictegravir-bic. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing